Estelle Vester Blokland News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Estelle vester blokland. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Estelle Vester Blokland Today - Breaking & Trending Today

Novartis' MS therapy Kesimpta reduces risk of disability progression regardless of relapses


Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
New post hoc data comes from phase 3 ASCLEPIOS trials
Novartis has revealed new post hoc data for its multiple sclerosis (MS) therapy Kesimpta only a few weeks after the drug received approval from the European Commission.
New analysis from the phase 3 ASCLEPIOS trials found that Kesimpta (ofatumumab) cut the risk of disability progression independent of relapse activity (PIRA) by up to 60% at three and six months when compared to Sanofi’s Aubagio (teriflunomide) in a subgroup of newly diagnosed, treatment-naive patients with relapsing multiple sclerosis (RMS).
The PIRA analysis also showed that over 50% of disability worsening events experienced by newly diagnosed and treatment-naive RMS patients occurred regardless of whether they also experienced relapses. ....

Sanofi Aubagio , Estelle Vester Blokland , Jacqueline Nicholas , Novarti Sensoready , Ohiohealth Ms Center , European Commission , Riverside Methodist Hospital , ஜாக்குலின் நிக்கோலஸ் , ஐரோப்பிய தரகு , ஆற்றங்கரை முறை மருத்துவமனை ,

Novartis study: Nurses and MS patients give thumbs-up to Kesimpta for ease of use


Mar 3, 2021 9:55am
Novartis presented positive study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum from nurses and patients using its Kesimpta auto-injector pen for MS. (Novartis)
Novartis nabbed FDA approval for Kesimpta to treat multiple sclerosis last year, but now it’s getting the thumbs-up from MS patients and nurses.
Novartis presented study data at the sixth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum in late February showing 84% preferred Kesimpta’s self-administration injector pen over rival administration methods.
The kudos from a small, 130-participant study come as Novartis bids to make Kesimpta a first-treatment option. Kesimpta’s chief rival Roche’s Ocrevus, which also works by targeting CD20-expressing B-cells is an infusion treatment. ....

Roche Ocrevus , Amy Perrin Ross , Estelle Vester Blokland , Americas Committee For Treatment , Research In Multiple Sclerosis Forum , Americas Committee , Multiple Sclerosis Forum , Uncover Rare Disease Insights , Accelerate Commercialization , Improve Patient , Perrin Ross , Multiple Sclerosis , Dtc Advertising , ஆமி பெர்ரின் ரோஸ் , அமெரிக்காக்கள் குழு க்கு சிகிச்சை , ஆராய்ச்சி இல் பல ஸ்க்லரோசிஸ் மன்றம் , அமெரிக்காக்கள் குழு , பல ஸ்க்லரோசிஸ் மன்றம் , விரைவுபடுத்து வணிகமயமாக்கல் , மேம்படுத்த நோயாளி , பெர்ரின் ரோஸ் , பல ஸ்க்லரோசிஸ் ,

Survey: MS Patients, Nurses Prefer Sensoready Pen for Injecting Kesimpta


4.6
(9)
People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey.
The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis Forum (ACTRIMS), taking place virtually Feb. 25–27.
“For people living with a chronic disease such as MS, access to highly effective treatments and maintaining flexibility in their lives is paramount,” Estelle Vester-Blokland, MD, global head neuroscience medical affairs, Novartis Pharmaceuticals, said in a press release. ....

United States , Amy Perrin Ross , Estelle Vester Blokland , University Of Lisbon , Americas Committee For Treatment , Biomedical Sciences , Novartis Pharmaceuticals , Society Of America , University Of Pittsburgh , Research In Multiple Sclerosis Forum , Multiple Sclerosis Forum , Neuroscience Program Coordinator , Loyola University Medical , Molecular Pathology , Molecular Biology , Universidade Nova De Lisboa , Managing Science Editor , ஒன்றுபட்டது மாநிலங்களில் , ஆமி பெர்ரின் ரோஸ் , பல்கலைக்கழகம் ஆஃப் லிஸ்பன் , அமெரிக்காக்கள் குழு க்கு சிகிச்சை , உயிர் மருத்துவ அறிவியல் , நோவர்த்திச் மருந்துகள் , சமூகம் ஆஃப் அமெரிக்கா , பல்கலைக்கழகம் ஆஃப் பிட்ஸ்பர்க் , ஆராய்ச்சி இல் பல ஸ்க்லரோசிஸ் மன்றம் ,